Allink Biotherapeutics Secures $42 Million Investment to Enhance Bispecific Antibody Development and Clinical Trials Allink Biotherapeutics has successfully raised $42 million in Series A funding, marking a significant step in advancing its bispecific antibody and ADC programs.

Allink Biotherapeutics Secures $42 Million Investment to Enhance Bispecific Antibody Development and Clinical Trials #China #Shanghai #Allink_Biotherapeutics #Lanchi_Ventures #Gaorong_Ventures